Medtronic reports first quarter fiscal 2025 financial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Goldman Sachs Reiterates Sell Rating on Medtronic, Inc. (MDT)
August 21, 2024 6:52 AM EDTGoldman Sachs analyst David Roman reiterated a Sell rating and $82.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "Following 1QFY25, we revise our model for (1) recent business performance; (2) updated market outlooks and competitive positioning; and (3) P&L assumptions. For FY25, we land just below EBIT margin targets, driven by sustained... More
Medtronic, Inc. (MDT) PT Raised to $94 at Oppenheimer
August 21, 2024 6:48 AM EDTOppenheimer analyst Steven Lichtman raised the price target on Medtronic, Inc. (NYSE: MDT) to $94.00 (from $92.00) while maintaining a Perform rating.
The analyst comments "Medtronic raised FY25 guidance low-end on organic sales (4.5-5% vs. 4-5% prior) and EPS (up slightly to $5.42-5.50 vs. $5.405.50). F1Q... More
Medtronic, Inc. (MDT) PT Raised to $106 at Wells Fargo
August 21, 2024 5:19 AM EDTWells Fargo analyst Larry Biegelsen raised the price target on Medtronic, Inc. (NYSE: MDT) to $106.00 (from $105.00) while maintaining a Overweight rating.
The analyst comments "Strong FQ1 rev beat on CVG, Neuroscience, and Diabetes strength. MDT reported FQ1 2025 rev of $8.0B (+5.3% organic) exceeded... More
Wolfe Research Reiterates Underperform Rating on Medtronic, Inc. (MDT)
August 21, 2024 5:13 AM EDTWolfe Research analyst Mike Polark reiterated an Underperform rating and $82.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "We rate MDT shares Underperform. We have an $82 target price which simplistically represents a 15x multiple on our FY2025 adjusted EPS forecast. On FY2025 EPS, our 15 P/E input represents a ~25% discount to current CY25 S&P 500 multiple of ~20x. This discount to the S&P sits in bottom quartile of the last decade. A discount is warranted, in our view, on track record and short-run expectations. Back 12 years, MDT EPS has... More
Deutsche Bank Reiterates Hold Rating on Medtronic, Inc. (MDT)
August 21, 2024 5:10 AM EDTDeutsche Bank analyst Pito Chickering reiterated a Hold rating and $85.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "MDT outperformed the broader market by 100 bps post this mornings print, with shareholders frustrated that MDT didnt outperform more post the beat-and-raise. MDT now... More
Medtronic hikes fiscal 2025 guidance as Q1 earnings beat expectations
August 20, 2024 7:01 AM EDTMedtronic (NYSE: MDT) reported first-quarter earnings that surpassed expectations and raised the outlook for the full fiscal 2025. The companys shares rose marginally in the premarket trade Tuesday.
For Q1, Medtronic reported earnings per share (EPS) of $1.23, topping the analyst estimate of $1.20. The company's revenue for the quarter matched the consensus estimate, coming in at $7.9 billion.
In its Cardiovascular segment, Medtronic generated $3.01 billion in... More
